The emergence of biologics that inhibit IL-17 has provided new avenues in the maintenance therapy of many autoimmune diseases [8], in which secukinumab has proven efficacy in psoriasis, psoriatic arthritis, and ankylosing spondylitis. This evidence concerns the gene IL17A and psoriatic arthritis.